Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.

"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

"AI can help clinicians translate unprecedented biological and clinical complexity into actionable insights," says Robert L. Ferris, MD, PhD.

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.